Matches in DBpedia 2016-04 for { ?s ?p "Secukinumab, trade name Cosentyx, is a human IL-17 inhibiting monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Secukinumab comment "Secukinumab, trade name Cosentyx, is a human IL-17 inhibiting monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass.".
- Q7444755 comment "Secukinumab, trade name Cosentyx, is a human IL-17 inhibiting monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass.".